#India #Biocomposites #Keele #Antimicrobials #STIMULAN®

Biocomposites Expands STIMULAN® Rapid Cure Approval in India

KEELE, England, Nov. 25, 2025 /PRNewswire/ – Biocomposites, a leader in medical devices, has just announced a significant advancement concerning its innovative product, STIMULAN® Rapid Cure. In a groundbreaking move, the Central Drugs Standard Control Organisation (CDSCO) of India has granted expanded approval for this unique calcium matrix product, allowing it to be combined with a broader spectrum of antibiotics and antifungals. This development is set to revolutionize how infections are managed during surgical procedures involving bone and surrounding soft tissues.

Enhanced Treatment Options

The newly approved use of STIMULAN® Rapid Cure enables medical professionals to precisely target infections more effectively than ever before. The product has now become the first calcium matrix authorized globally to mix with antifungal agents—a milestone that empowers surgeons operating in India. Tailoring antimicrobial treatment strategies to meet individual patient needs will undoubtedly improve patient outcomes in surgical practices where infection management is critical.

Global Impact

STIMULAN® Rapid Cure is well-recognized in over 60 countries and has made its mark as a vital component in infection control within various surgical disciplines. With each year, more than 150,000 patients worldwide utilize this product, showcasing its importance across specialties like orthopedics, trauma, and sports injuries.

Michael Harris, CEO of Biocomposites, expressed enthusiasm regarding this achievement, emphasizing the product’s crucial role in addressing the ever-growing challenge of antimicrobial resistance. “Surgeons now have the flexibility to choose antimicrobial treatments tailored specifically for every patient, thereby playing a vital role in managing infection risks more efficiently,” he stated.

Combatting Surgical Site Infections

Surgical site infections pose a significant threat and can drastically influence mortality rates globally. By allowing for improved combinations of antimicrobial therapies, the expanded approval for STIMULAN® Rapid Cure is a vital tool that equips healthcare professionals to combat infection effectively. The innovative product not only facilitates wound healing but also attains a holistic approach to infection management.

Furthermore, the versatility of STIMULAN® Rapid Cure reinforces its reputation as a pioneering product in the field of surgery. Leading medical professionals around the world are increasingly recognizing the potential of combining different antimicrobials to tailor treatment according to specific clinical situations.

A Look Ahead

As the healthcare landscape continues to evolve, the implications of this expanded approval are far-reaching. As the first in the world to gain such permission, India stands at the forefront of advancing surgical techniques and infection management strategies. This will significantly enhance the treatment strategies employed by surgeons, making sure they are equipped with the most relevant and effective options available.

Biocomposites remains committed to innovation and excellence in surgical care. By investing in research and development, they aim to continue producing world-leading products that advance infection management across medical fields.

For more information about Biocomposites and its innovative solutions, please visit biocomposites.com.